Feature

ASCO at 50 … we’ve come a long way, we know a lot, but we’ve only just begun


 

I recently had both the pleasure and the challenge of attending ASCO 2014, the annual meeting of the American Society of Clinical Oncology. It was my first official ASCO meeting, and as an almost-third-year fellow in oncology, no amount of reading, research, scheduling, ASCO 2014 iPad app organizing, or even attending the day 1 early morning How to Navigate the Annual Meeting seminar could have prepared me for the experience…

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Drugs approved in 2013
MDedge Hematology and Oncology
Consumer Reports: Sunscreen SPF claims largely inaccurate
MDedge Hematology and Oncology
ASCO 2014: Dr. Jeffrey A. Sosman gives his top picks in melanoma research
MDedge Hematology and Oncology
High rate of durable responses to pembrolizumab in metastatic melanoma
MDedge Hematology and Oncology
‘Unprecedented’ overall survival of metastatic melanoma
MDedge Hematology and Oncology
VIDEO: Pembrolizumab may herald new hope in advanced melanoma
MDedge Hematology and Oncology
VIDEO: Advanced melanoma on brink of immunotherapy ‘revolution’
MDedge Hematology and Oncology
VIDEO: Drug combo delivers ‘unprecedented’ metastatic melanoma survival
MDedge Hematology and Oncology
Trametinib plus dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations
MDedge Hematology and Oncology
Cutaneous Melanoma
MDedge Hematology and Oncology